Amoy Diagnostics Co., Ltd. (SHE:300685)

China flag China · Delayed Price · Currency is CNY
20.02
-0.04 (-0.20%)
Mar 9, 2026, 3:04 PM CST
-16.20%
Market Cap 7.74B
Revenue (ttm) 1.13B
Net Income (ttm) 290.10M
Shares Out 386.86M
EPS (ttm) 0.74
PE Ratio 27.12
Forward PE 18.86
Dividend 0.30 (1.50%)
Ex-Dividend Date Jun 3, 2025
Volume 4,178,034
Average Volume 5,139,854
Open 19.86
Previous Close 20.06
Day's Range 19.51 - 20.09
52-Week Range 19.27 - 26.15
Beta 0.71
RSI 36.60
Earnings Date Apr 28, 2026

About Amoy Diagnostics

Amoy Diagnostics Co., Ltd. engages in research and development, production, sale, and supporting services of tumor precision medical diagnostic products in China and internationally. The company offers AmoyDx homologous recombination deficiency (HRD) focus panel solutions, evaluates PARP inhibitor-related biomarkers and advances targeted treatment research in ovarian cancer; AmoyDx comprehensive panel, a sequencing-based test capable of detecting a range of alterations; AmoyDx HRD complete panel, detects genetic aberrations across HRR genes and... [Read more]

Sector Healthcare
Founded 2008
Employees 1,144
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300685
Full Company Profile

Financial Performance

In 2024, Amoy Diagnostics's revenue was 1.11 billion, an increase of 6.27% compared to the previous year's 1.04 billion. Earnings were 254.86 million, a decrease of -2.53%.

Financial Statements

News

There is no news available yet.